---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-25-000032"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2025-11-28T23:59:59+00:00"
generated_at: "2026-05-16T16:11:10.294362+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# AbCellera dismisses KPMG, appoints EY as auditor for FY2026 after tender

## Summary
- Audit Committee dismissed KPMG effective after 2025 audit; no disagreements or reportable events in 2023-2025.
- EY selected as new independent auditor for FY2026 following a formal tender process.
- KPMG's audit opinions for FY2023 and FY2024 were unqualified with no adverse opinions.

## SEC filing metadata
- accession: 0001703057-25-000032
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2025-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 4.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305725000032/0001703057-25-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305725000032/abcl-20251124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-25-000032
- JSON: https://secwatch.observer/filing/0001703057-25-000032.json
- Plain text: https://secwatch.observer/filing/0001703057-25-000032.txt

## Source-grounded claims
- claim_id: 78efeeca7be7b291e496c9242628506e700c2653
  claim: AbCellera Biologics Inc. dismissed KPMG LLP as its auditor.
  evidence_excerpt: On November 24, 2025, the Audit Committee of the Board of Directors (the "Audit Committee") of AbCellera Biologics Inc. (the "Company") approved the dismissal of KPMG LLP ("KPMG") as the Company's independent registered public accounting firm, effective following the completion of KPMG's audit of the Company's consolidated financial statements for the fiscal year ending December 31, 2025, and the filing of the Company's Annual Report on Form 10-K for that fiscal year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703057/000170305725000032/0001703057-25-000032-index.htm
- claim_id: 82b24b842636501ce4619d6eb60d35f7fa7b0143
  claim: AbCellera Biologics Inc. engaged Ernst & Young LLP as its auditor.
  evidence_excerpt: on November 24, 2025, the Audit Committee selected Ernst & Young LLP ("EY") as the Company's new independent registered public accounting firm for the fiscal year ending December 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703057/000170305725000032/0001703057-25-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.